StemSight: curing blindness with stem cells

StemSight is developing off-the-shelf stem cell therapies to cure blindness.

We aim to solve the global shortage of corneal donor tissue by producing high-quality tissue products using allogeneic induced pluripotent stem cells (iPSCs) and biomaterials.

Our lead product is aimed at a rare but severe form of corneal blindness, limbal stem cell deficiency (LSCD), for which there are currently no valid treatment options.

The company's innovations have arisen from extensive academic research, and the company has spun out from Tampere University, Finland in 2021. StemSight is a rare kind of deep-tech startup, as all of its scientific founders are women.